Advertisement

Klinische Wochenschrift

, Volume 62, Issue 13, pp 631–639 | Cite as

Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II

Evidence against a primary extrapancreatic receptor effect
  • W. P. Bieger
  • R. Dlugosch
  • A. Rettenmeier
  • H. D. Holler
  • H. Bert
  • W. Schwarz
  • W. Fiehn
  • J. Merkt
  • H. Weicker
Originalien

Summary

Recently in vitro evidence has been presented that sulfonylurea derivatives exert their chronic extrapancreatic effect by increasing the number of cellular insulin receptors. To ascertain if this receptor effect holds in vivo, we performed a randomized double-blind study on 21 type I (0.3 ng/ml residual C-peptide secretory capacity after glucose/glibenclamide stimulation), and on 19 insulin treated type II (2.0 ng/ml C-peptide) diabetics. The patients received for six weeks 10 mg/d of glibenclamide in addition to insulin. Insulin binding was initially lower in type II (4.7±0.75% per 107 monocytes and 6.39±1.08% per 4.5×109 erythrocytes) than in type I diabetic patients (5.1±0.48% and 7.95±0.88% respectively) and in 12 normal subjects (5.25±0.48 and 8.1±0.94% respectively). Glibenclamide normalized the number of monocyte receptors (from 4.14 to 5.49×104 sites/cell) in type II patients, but was without effect in type I diabetics. Blood glucose was significantly reduced (240 to 182 mg/dl;p=0.02) in the type II group with a concomitant decrease in glycosylated hemoglobin from 12.4 to 10.5% (p=0.01). Most of the effect occured during the first week of treatment. Glibenclamide was the more effective the worse the initial metabolic state (r=−0.93;p=0.001). Erythrocyte insulin receptors decreased markedly in both groups, perhaps due to a sulfonyl urea-induced change in erythrocyte plasma survival time. It is concluded that sulfonylurea treatment is a valuable adjunct in reducing the insulin resistance in insulin treated type II diabetics. The effect depends on the availability of endogenous insulin, thus exhibiting only partly extrapancreatic character. The receptor effect in the type II patients may be secondary to the metabolic improvement.

Key words

Sulfonylurea Insulin therapy Diabetes mellitus Insulin receptor Monocytes Erythrocytes 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Yalow RS, Black H, Berson SA (1960) Comparison of plasma insulin levels following administration of tolbutamide and glucose. Diabetes 9:356–362Google Scholar
  2. 2.
    Vallence-Owen J, Joplin GF, Fraser R (1959) Tolbutamide control of diabetes mellitus: Clinical resposiveness and insulin reserve. Lancet 2:584–586Google Scholar
  3. 3.
    Reaven G, Dray J (1967) Effect of chlorpropramide on serum glucose and immuno-reactive insulin concentrations in patients with maturity onset diabetes mellitus. Diabetes 16:487–492Google Scholar
  4. 4.
    Lunetta M, Leonardi R, Rapisarda S, Mughini L (1981) Effects of short- and long-term glibenclamide treatment on the response of pancreatic alpha- and beta cells to oral glucose loading in adult-onset diabetes. Curr Ther Res 30:50–62Google Scholar
  5. 5.
    Feldmann JM, Lebovitz HE (1969) Appraisal of the extrapancreatic actions of sulfonylureas. Arch Intern Med 123:314–322Google Scholar
  6. 6.
    Olefsky JM, Reaven GM (1976) Effects of sulfonylurea therapy on insulin binding to mononuclear leukocytes of diabetic patients. Am J Med 60:89–95Google Scholar
  7. 7.
    Beck-Nielsen H, Pedersen O, Lindskov HO (1979) Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide. Acta Endocrinol 90:451–462Google Scholar
  8. 8.
    Bachmann W, Böttger J, Haslbeck M, Mehnert H (1979) Extrapancreatic action of sulfonylureas: effect of gliquidone on insulin and glukagon binding to rat liver plasma membranes. Eur J Clin Invest 9:411–415Google Scholar
  9. 9.
    Joost HG, Arend W, Holze SA (1982) Effects of tolbutamide on insulin binding to isolated fat cells of the rat. Biochem Pharmacol 31:1227–1231Google Scholar
  10. 10.
    Prince MJ, Olefsky JM (1980) Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. J Clin Invest 66:608–611Google Scholar
  11. 11.
    Feinglos MN, Lebovitz HE (1978) Sulfonylureas increase the number of insulin receptors. Nature 276:184–185Google Scholar
  12. 12.
    Beck-Nielsen H, Pedersen O, Lindskov HO (1979) Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol 90:103–112Google Scholar
  13. 13.
    Kahn CR, Roth J (1976) Insulin receptors in disease states. In: Levey GS (ed) Hormone-receptor interaction. Molecular aspects. M Dekker, New York, p 1–42Google Scholar
  14. 14.
    Tucker SR, Pierre RV, Jordon RF (1977) Rapid identification of monocytes in a mixed mononuclear cell preparation. J Immunol Methods 14:267–269Google Scholar
  15. 15.
    Kaplow LS (1965) Simplified myeloperoxidase stain using benzidine dihydrochloride. Blood 26:215–219Google Scholar
  16. 16.
    Gambhir KK, Archer JA, Bradley CJ (1978) Characteristics of human erythrocyte insulin receptors. Diabetes 27:701–708Google Scholar
  17. 17.
    Turner BM, Fisher RA, Harris H (1974) The age related loss of activity of four enzymes in the human erythrocyte. Clin Chim Acta 50:85–95Google Scholar
  18. 18.
    Spicer KM, Allen RC, Buse MG (1978) A simplified assay of hemoglobin A1c in diabetic patients by use of isoelectric focusing and quantitative microdensitometry. Diabetes 27:384–388Google Scholar
  19. 19.
    Scatchard G (1949) The attraction of proteins for small molecules and ions. Ann N Y Acad Sci 42:475–481Google Scholar
  20. 20.
    De Meyts P, Roth J (1975) Cooperativity in ligand binding: a new graphic analysis. Biochem Biophys Res Common 66:1118–1126Google Scholar
  21. 21.
    Archer JA, Gordon P, Roth J (1974) Defect in insulin binding to receptors in obese man. Amelioration with caloric restriction. J Clin Invest 55:166–169Google Scholar
  22. 22.
    Grodsky GM, Epstein GH, Fanska R, Karam JH (1977) Pancreatic action of the sulfonylureas. Fed Proc 36:2714–2719Google Scholar
  23. 23.
    Duckworth WC, Solomon SS, Kitabchi AE (1972) Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. J Clin Endocrinol Metab 35:585–591Google Scholar
  24. 24.
    Maloff BL, Lockwood DH (1981) In vitro effects of a sulfonylurea on insulin action in adipocytes. Potentiation of insulin-stimulated hexose transport. J Clin Invest 68:85–90Google Scholar
  25. 25.
    Vigneri R, Pezzino V, Wong KY, Goldfine JD (1982) Comparison of the in vitro effect of biguanides and sulfonylureas on insulin binding to its receptors in target cells. J Clin Endocrinol Metab 54:95–100Google Scholar
  26. 26.
    Nowak SM, McCaleb ML, Lockwood DM (1983) Extrapancreatic action of sulfonylureas: hypoglycemic effects are not dependent on altered insulin binding or inhibition of transglutaminase. Metabolism 32:398–402Google Scholar
  27. 27.
    Levey GS (1977) The effects of sulfonylureas on peripheral metabolic processes. Fed Proc 36:2720–2723Google Scholar
  28. 28.
    Veseley DL (1982) Direct effect of glibenclamide on guanylate cyclase activity in the rat in vitro. Diabetologia 22:269–272Google Scholar
  29. 29.
    Lockwood DH, Maloff BZ, Nowak SM, McCaleb ML (1983) Extrapancreatic effect of sulfonylureas. Potentiation of insulin action through post-binding mechanisms. Am J Med 67:102–108Google Scholar
  30. 30.
    Grunberger G, Ryan J, Gordon P (1982) Sulfonylureas do not affect insulin binding or glycemic control in insulin-dependent diabetics. Diabetes 31:890–896Google Scholar
  31. 31.
    Friedlander EO (1957) Use of tolbutamide in insulin-resistant diabetes. New Engl J Med 251:11–16Google Scholar
  32. 32.
    Fabrykant M, Ashe BJ (1959) Combined insulin-tolbutamide therapy in the management of insulin-dependent diabetes mellitus. Ann NY Acad Sci 82:585–588Google Scholar
  33. 33.
    Volk BW, Lazarus SS (1959) Significance of effectiveness of combined insulin-orinase treatment in maturity-onset diabetes. Am J Med Sci 237:1–4Google Scholar

Copyright information

© Springer-Verlag 1984

Authors and Affiliations

  • W. P. Bieger
    • 1
  • R. Dlugosch
    • 1
  • A. Rettenmeier
    • 1
  • H. D. Holler
    • 1
  • H. Bert
    • 1
  • W. Schwarz
    • 1
  • W. Fiehn
    • 1
  • J. Merkt
    • 1
  • H. Weicker
    • 1
  1. 1.Medizinische Poliklinik Abteilung Pathophysiologie und SportmedizinUniversität HeidelbergHeidelbergBundesrepublik Deutschland

Personalised recommendations